BHVN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Biohaven Ltd (BHVN) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows bearish technical indicators, limited positive catalysts, and weak financial performance. While analysts have mixed views, the lack of significant near-term catalysts and the company's financial struggles make it prudent to hold off on investment for now.
The stock is exhibiting bearish technical indicators: the MACD is negative and expanding downward, RSI is neutral at 37.8, and moving averages suggest a bearish trend (SMA_200 > SMA_20 > SMA_5). The price is trading near a key support level of 11.02, with resistance at 11.91.
Insider buying has increased significantly by 3226.99% over the last month, indicating confidence from insiders. Analysts from Goldman Sachs and RBC Capital have issued positive ratings with price targets of $23 and $22, citing the potential of BHV-1400 in IgA nephropathy and the company's improved financial position.
The stock recently experienced a 3.13% drop in regular market trading and a 0.36% decline in post-market trading. The company's Phase II study for BHV-7000 in major depressive disorder failed, leading to mixed analyst sentiment. Additionally, the financials are weak, with negative net income (-$173.44M) and declining EPS (-3.53% YoY).
In Q3 2025, the company reported no revenue growth (0% YoY) and a net loss of $173.44M, though this was an 8.20% improvement YoY. EPS dropped by 3.53% YoY to -1.64, reflecting ongoing financial challenges.
Analyst sentiment is mixed. Goldman Sachs and RBC Capital are optimistic, with price targets of $23 and $22, respectively, citing potential in IgA nephropathy and an improved financial position. However, H.C. Wainwright downgraded the stock to Neutral with an $11 price target, citing fewer ways to win and limited confidence in upcoming catalysts.
